| Symbol | ERNA |
|---|---|
| Name | ERNEXA THERAPEUTICS INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 1035 CAMBRIDGE STREET,SUITE 18A, CAMBRIDGE, Massachusetts, 02141, United States |
| Telephone | +1 617 - 798-6700 |
| Fax | — |
| — | |
| Website | https://www.ernexatx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000748592 |
| Description | Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease. Ernexas core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexas allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Ernexa Therapeutics Inc. <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0001104659-26-060524 <b>Size:</b> 14 KB
Read moreNew Form ARS - Ernexa Therapeutics Inc. <b>Filed:</b> 2026-05-11 <b>AccNo:</b> 0001493152-26-022288 <b>Size:</b> 1 MB
Read moreNew Form DEFA14A - Ernexa Therapeutics Inc. <b>Filed:</b> 2026-05-11 <b>AccNo:</b> 0001493152-26-022284 <b>Size:</b> 1 MB
Read moreErnexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101
Read moreErnexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models
Read more(99% Neutral) ERNEXA THERAPEUTICS INC. (ERNAW) Announces Executive Changes
Read moreNew Form DEF 14C - Ernexa Therapeutics Inc. <b>Filed:</b> 2026-04-13 <b>AccNo:</b> 0001493152-26-016310 <b>Size:</b> 76 KB
Read moreNew Form PRE 14C - Ernexa Therapeutics Inc. <b>Filed:</b> 2026-04-01 <b>AccNo:</b> 0001493152-26-014709 <b>Size:</b> 76 KB
Read moreErnexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read more